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Facts
Long noncoding RNAs (lncRNAs) regulate cell proliferation in osteosarcoma. LncRNAs regulate cell invasion and chemotherapeutic drug resistance in human osteosarcoma. LncRNAs function as biomarkers and independent prognostic indicators with respect to osteosarcoma therapy.
Open Questions
How do lncRNAs regulate osteosarcoma progression and invasion? How do lncRNAs regulate osteosarcoma chemotherapeutic drug resistance? Can lncRNAs be used as biomarkers or prognostic indicators with respect to human osteosarcoma treatment?
Osteosarcoma is the most common malignant bone tumor in children and adolescents. It is a genetically unstable and highly malignant mesenchymal tumor of bone characterized by structural chromosomal alterations. 1, 2 Malignant osteosarcoma cells produce osteoid matrix and fibrillary stroma. 3 The most common osteosarcoma subtypes are osteoblastic osteosarcoma, chondroblastic osteosarcoma, and fibroblastic sarcoma. 4, 5 Osteosarcoma occurs predominantly in adolescents and young adults and accounts for~5% of childhood cancers. Most osteosarcoma patients are diagnosed under the age of 25 years, and the disease occurs more often in males than in females. 6 Osteosarcoma often exhibits locally invasive growth. Pulmonary metastases are often seen in patients with aggressive tumors. Both biopsy findings and classic X-ray findings contribute to the diagnosis of osteosarcoma and yield important information that can be used to select appropriate therapies. 7, 8 In most osteosarcoma patients, chemotherapy and/or radiation therapy are usually administered before or after surgery to prevent tumors from spreading throughout the body. However, patients with distant metastases still fare poorly, as the 5-year survival rate in these patients is~20%. 9, 10 Thus, developing comprehensive and multidimensional treatments for osteosarcoma is necessary, and gene therapies using viral vectors, immune therapies, antiangiogenic therapies, and proapoptotic therapies have been investigated regarding their application in patients with osteosarcoma.
To date, the molecular mechanism underlying osteosarcoma development remains unclear. The majority of previous studies have focused on protein-coding genes as crucial components involved in the progression and metastasis of osteosarcoma and have overlooked the vast landscape of noncoding genes.
Since the invention of DNA sequencing methods and the completion of the draft human genome sequence, researchers have found that only 1.5% of 3.2 billion nucleotide pairs code for proteins and that the other 98.5% of DNA sequences do not code for proteins. These sequences are recognized as junk sequences that have accumulated because of the process of evolution.
11,12 ENCODE (Encyclopedia of DNA Elements) projects postulate that 80% of genome sequences are transcribed into primary transcripts and have biochemical functions. 13, 14 The concept of 'junk DNA' has rapidly attracted the attention of researchers. According to their biological functions, noncoding RNAs can be divided into housekeeping noncoding RNAs and regulatory noncoding RNAs. [15] [16] [17] Housekeeping noncoding RNAs comprise ribosomal RNAs, [18] [19] [20] transfer RNAs, 21, 22 small nuclear RNAs, [23] [24] [25] small nucleolar RNAs, [26] [27] [28] guide RNAs, [29] [30] [31] [32] and telomerase RNAs. 33, 34 Regulatory noncoding RNAs comprise small interfering RNAs (siRNAs), [35] [36] [37] micro RNAs (microRNA), [38] [39] [40] piwi-interacting RNAs, [41] [42] [43] and long noncoding RNAs (lncRNAs). 44, 45 lncRNAs are a large and diverse class of non-protein-coding transcripts longer than 200 nucleotides. 46, 47 lncRNAs have recently gained widespread attention and have been shown to have crucial roles in various biological regulatory processes. lncRNA sequences are conserved, and lncRNA expression profiles in adult tissues are broad. lncRNA messenger RNAs (mRNAs) are generally less abundant than protein-coding mRNAs but exhibit stronger tissue-and cell-specific lncRNA expression patterns. 48, 49 Most lncRNAs are transcribed by RNA polymerase II enzymes that lack open-reading frames and are expressed in specific tissues and/or during specific developmental stages, demonstrating that the genes encoding these molecules are strictly regulated with respect to tissue development. Previous research has mainly focused on microRNAs and siRNAs. lncRNAs have recently been found to be involved in development, differentiation, and proliferation, as well as cell cycle regulation and programmed cell death. [50] [51] [52] [53] They also have important roles in the progression and metastasis of various tumors, such as colon cancer, liver cancer, breast cancer, bladder cancer, and cervical cancer 51, [54] [55] [56] [57] [58] [59] ( Figure 1 ). In this paper, we reviewed the biological functions of lncRNAs and the molecular mechanisms underlying these functions with respect to osteosarcoma progression. Chemotherapy drug resistance remains an obstacle affecting osteosarcoma treatment. We therefore also summarized the lncRNAs that are correlated with chemotherapeutic drug resistance in osteosarcoma therapy. Furthermore, we summarized several lncRNAs that can function as independent prognostic indicators of overall survival and can serve as useful biomarkers of osteosarcoma progression and prognosis. An overview of the lncRNAs that are associated with osteosarcoma is shown in Table 1 .
LncRNA Regulates Signaling Pathways in Osteosarcoma
Developing effective and targeted therapies for osteosarcoma is dependent on gaining an improved understanding of the molecular mechanisms underlying osteosarcomagenesis, proliferation, invasion, and metastasis. 60 To date, the molecular mechanism underlying osteosarcoma development has not been elucidated. It is known that Wnt signaling is involved in osteosarcoma development, metastasis, and drug resistance. For example, inhibiting Wnt signaling by targeting c-Met, a Wnt-regulated proto-oncogene, was shown to be useful for treating osteosarcoma, suggesting that the Wnt signaling pathway is involved in osteosarcoma development and metastasis. 61 Chemotherapeutic drug resistance represents a major obstacle with respect to osteosarcoma treatment, due in part to phenotypic cell transitions toward stem-like phenotypes caused by exposure to conventional chemotherapeutics. 62, 63 However, the combination of a Wnt/β-catenin signaling pathway inhibitor and doxorubicin prevented the upregulation of factors linked to these types of transitions and was thus envisaged as a means of overcoming adaptive resistance. 64 Aberrant hedgehog (Hh) signaling pathway activity has been observed in osteosarcoma cell lines, as well as in primary human osteosarcoma tissue specimens, and exerts promigratory effects leading to the development of osteoblastic osteosarcoma. 65 Other studies have also demonstrated that dysregulated Hh signaling contributes to poor clinical outcomes in osteosarcoma therapy. 66, 67 Bone morphogenetic protein (BMP) signaling pathways have been reported to induce mesenchymal stem cell osteogenic commitments and terminal differentiation, which is initiated by BMP ligand heterodimer (BMPR I and II) binding and signal transduction through the Smad pathway, as well as mitogenactivated protein kinase (MAPK) phosphorylation. [68] [69] [70] [71] In particular, of the 31 different types of known BMP ligands, BMP-2, -4, -6, -7, and -9 have significant roles in osteogenesis induction in osteosarcoma. [72] [73] [74] Moreover, the Notch pathway has been described as an oncogene that is involved in osteosarcoma proliferation, migration, invasiveness, and oxidative stress resistance, as well as the expression of markers associated with stemness or tumor-initiating cells. [75] [76] [77] [78] Moreover, this pathway has a vital role in regulating tumor angiogenesis and vasculogenesis in osteosarcoma. 79 The phosphatidylinositol 3-kinase (PI3K)/Akt pathway is also The patients with low lncRNA MEG3 expression had a shorter overall survival MEG3 was an independent predictor to overall survival of osteosarcoma patients. BYL719, a PI3K inhibitor, 89 and LY294002. 90 All these signaling pathways are interconnected to regulate osteosarcoma progression and migration.
To date, few studies have reported the roles of lncRNAs in osteosarcoma osteogenesis, development, invasion, metastasis or chemotherapy resistance. Alterations in the expression of several lncRNAs have been observed in osteosarcoma. Li et al. 91 detected the expression profiles of numerous lncRNAs via microarray analysis and observed several differentially expressed lncRNAs in osteosarcoma tissues compared with paired adjacent noncancerous tissues. In particular, 25 733 lncRNAs were expressed in osteosarcoma, including 403 consistently over-regulated lncRNAs involved in 34 pathways and 798 consistently under-regulated lncRNAs involved in 32 pathways, across all samples (2.0-fold, Po0.05), suggesting that lncRNAs can function as therapeutic targets and serve as novel candidate biomarkers with respect to osteosarcoma diagnosis and prognosis.
91 P50-associated COX-2 extragenic RNA (PACER) was overexpressed in clinical osteosarcoma tissues and cell lines influenced by DNA methylation, activated the COX-2 gene in an NF-κB-dependent manner and functioned as an oncogene in osteosarcoma. 92 Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), one of the first cancerassociated lncRNAs to be identified, is expressed in numerous tissues, is highly abundant in neurons and is involved in regulating the recruitment of SR family pre-mRNA-splicing factors to sites of transcription involved not only in nuclear processes but also in synapse function. 93 Aberrant MALAT1 expression has been observed in many types of tumors, including hepatocellular carcinoma, cervical cancer, breast cancer, ovarian cancer, and colorectal cancer. Dong et al. 94 found that MALAT1 was highly expressed in human osteosarcoma tissues and that its expression level was closely correlated with pulmonary metastasis. Moreover, they found that MALAT1 knockdown suppressed human osteosarcoma cell proliferation, invasion, and metastasis in vitro and in vivo. They also explored the molecular mechanisms underlying the function of MALAT1 in osteosarcoma and observed that MALAT1 inhibited tumor growth and metastasis via the PI3K/ AKT signaling pathway, as the expression levels of proliferating cell nuclear antigen, matrix metallopeptidase 9 (MMP-9), phosphorylated PI3Kp85α, and Akt were significantly decreased in MALAT1-knockdown cells. 94 Cai et al.
95
observed similar results in MALAT1 siRNA-treated osteosarcoma cells. They showed that MALAT1 knockdown inhibited osteosarcoma cell proliferation and migration, induced osteosarcoma cell cycle arrest and cell apoptosis, and delayed tumor growth in an osteosarcoma xenograft model. Specifically, they found that MALAT1 siRNA administration decreased the protein expression levels of RhoA and its downstream effectors, the Rho-associated coiled-coil containing protein kinases (ROCKs). Consistent with these studies, high-dose 17β-estradiol (E2) treatment markedly downregulated MALAT1-mediated osteosarcoma cell proliferation, migration, invasion, and metastasis by upregulating miR-9 in E2-dose-dependent and ER-independent manners. In addition, MALAT1 downregulation promoted the formation of the SFPQ/PTBP2 complex. 96 Moreover, Taniguchi et al.
97
found that MALAT1 contains a theoretical Myc-6-target sequence that includes an E-box-like motif (at positions − 258 to − 251). Interestingly, knockdown of the putative Myc-6 target MALAT1 obviously impaired MG63 cell growth. In general, Myc-6 appears to exert its tumor-suppressive effects, at least in part, through the specific downregulation of MALAT1. The Hh signaling pathway hass important roles in vertebrate embryonic development and growth regulation, functions as a morphogen and mitogen, and is normally deactivated after embryogenesis. However, Hh signaling is reactivated and upregulated in various cancers, including osteosarcoma, resulting in high levels of yes-associated protein 1 (Yap1) expression. Yap1, a potent oncogene expressed in both human and mouse tumor tissues, is amplified in various cancers. Hh signaling inhibition reduces Yap1 expression, and Yap1 knockdown significantly inhibits tumor progression. Chan et al. 98 found that aberrant Hh signaling in mature osteoblasts is responsible for the pathogenesis of osteoblastic osteosarcoma. Moreover, Hh signaling upregulation and Yap1 overexpression lead to aberrant lncRNA H19 expression in malignant osteosarcoma. The lncRNAs involved in osteosarcoma and osteosarcomarelated signaling pathways are shown in Figure 2 .
LncRNA Regulates Osteosarcoma Metastasis
Distant metastases are commonly observed in patients with osteosarcoma after surgery. It is estimated that metastases have been found in 85% of patients with osteosarcoma. The most common site of osteosarcoma metastasis is the lung. Metastatic osteosarcoma is difficult to control, and respiratory symptoms appear only in the setting of extensive involvement. Osteosarcoma also metastasizes to other bone and soft tissue locations. This issue is still controversial, as some authors have argued that bone metastases may actually be multifocal osteosarcomas rather than actual metastases. Death from osteosarcoma is usually a result of pulmonary metastasis and respiratory failure because of widespread progression.
Tumor invasion and metastasis is a multilink, multistep complex process comprising invasion, intravasation, dissemination, extravasation, and colonization. Briefly, tumor cells alter cell-extracellular matrix (ECM) interactions at the primary tumor site, escape from the primary site and invade adjacent tissues, and translocate through the vasculature to migrate to other systems. Then, these metastatic cancer cells anchor to distant vessel walls and extravasate into their destination tissues (Figure 3 ) before finally proliferating from microscopic growths to form secondary tumors.
Adhesion molecules, angiogenic factors, proteolytic enzymes, tumor metastasis-related factors, and metastasis suppressors are involved in migration and metastasis. MMPs are a family of proteolytic enzymes and are the key proteases involved in digesting components of the ECM and surface receptors. MMPs has an important role in tumor invasion and metastasis by degrading the ECM and basement membrane to remodel the tumor microenvironment and promote tumor angiogenesis. Conversely, MMP activity is suppressed by endogenous tissue inhibitors of metalloproteinases (TIMPs), specific MMP inhibitors. The levels of endogenous MMPs and TIMPs contribute to imbalances between MMPs and TIMPs and regulate ECM degradation and deposition. It has been reported that the levels of MMP-2 and MMP-9 secretion are elevated in several types of human cancers and that these elevations are associated with a poor prognosis. 99 During osteosarcoma cell invasion and migration, several lncRNAs reportedly promote or inhibit cell proliferation and invasion by regulating MMP-2 and MMP-9 secretion. 100 Osteosarcoma cell invasion and metastasis and the lncRNAs associated with these processes are shown in Figure 4 .
The HOX antisense intergenic RNA (HOTAIR), a wellknown lncRNA, is involved in the pathogenesis and progression of multiple tumors. HOTAIR is commonly overexpressed in osteosarcoma, and its knockdown significantly inhibits cellular proliferation and invasion by decreasing MMP-2 and MMP-9 section in osteosarcoma cells. Meanwhile, high HOTAIR expression levels are significantly associated with advanced tumor stages, high histological grades, and poor prognoses. Thus, HOTAIR may be an important target in the treatment of human osteosarcoma. 101 It has been reported that the small nucleolar RNA host gene 12 (SNHG12) promotes cell proliferation and migration by upregulating angiomotin (AMOT) gene expression in human osteosarcoma cells. 102 In particular, tissue samples from primary osteosarcomas (n = 20) and adjacent normal tissues (n = 20), as well as samples from the osteosarcoma cell lines SAOS-2, MG63, and U2OS and the human osteoblast cell line hFOB (OB3), were studied using quantitative real-time polymerase chain reaction to detect SNHG12 expression. They found that SNHG12 mRNA expression was upregulated in osteosarcoma tissues and cell lines compared with normal tissues and cells and that SNHG12 knockdown suppressed cell proliferation and migration but did not affect cell apoptosis. These findings suggest that SNHG12 lncRNA promotes cell Figure 3 Tumor invasion and metastasis is a multilink, multistep complex process. Tumor cells at primary tumor sites invade surrounding tissues, migrate through the blood or lymph and localize in distal targeted tissues. This process is divided into the following five stages: invasion, intravasation, dissemination, extravasation, and colonization Figure 2 Osteosarcoma cell proliferation is regulated by lncRNAs, including H19, MALAT1, ANCR, and PACER. These osteosarcoma-related lncRNAs are involved in the PI3K/Akt signaling pathway, NF-κB signaling pathway, and Hh/Yap1 signaling pathway proliferation and migration by upregulating AMOT gene expression in osteosarcoma cells in vivo and in vitro and are consistent with the findings of previous studies involving human gastric cancer patients, which showed that upregulation of SNHG15 lncRNA expression promotes cell proliferation and invasion by regulating MMP-2/MMP-9 expression. 103 Mammalian genomes encode numerous natural antisense transcripts that are at least partially complementary to their sense transcripts. FGFR3 antisense transcript 1 (FGFR3-AS1) increased FGFR3 mRNA stability and upregulated FGFR3 expression via antisense pairing with FGFR3 3′-UTR. Increased FGFR3-AS1 expression was correlated with large tumor size, advanced Enneking stage, metastasis and poor survival. FGFR3-AS1 knockdown inhibited xenograft tumor growth of osteosarcoma cells in vitro and in vivo. Therefore, lncRNA FGFR3-AS1 promoted osteosarcoma growth by regulating its natural antisense transcript FGFR3. 104 
LncRNA and Osteosarcoma Cell Proliferation
Cancer occurrence is characterized by uncontrolled cell cycle activity, including uncontrolled DNA replication and parental cell division. 105 Imbalances between programmed cell death and cell proliferation contribute to the development of various cancers. Both oncogene activation and tumor suppressor gene inactivation lead to cancer occurrence and development. 106, 107 In osteosarcoma, lncRNAs also exhibit oncogenic properties or act as tumor suppressors to control osteosarcoma progression by regulating cell cycle progression or cell apoptosis to regulate cell proliferation or migration. Antidifferentiation noncoding RNA (ANCR) is a newly identified oncogenic lncRNA that has an important role in the maintenance of cell undifferentiation. ANCR knockdown significantly inhibited U2OS and SAOS cell proliferation and U2OS cell colony formation and arrested the U2OS cell cycle at the G0/G1 phase. Moreover, ANCR regulated and controlled cell cycles by regulating the endogenous levels of cell cycle-related proteins, including p21, CDK2, and CDK4. 108 The levels of taurine-upregulated gene 1 (TUG1) and one of its transcript variants (n377360) were significantly higher in osteosarcoma tissues compared with that in matched non-tumorous tissues. Consistent with this finding, TUG1 and n377360 suppression by siRNA significantly impaired osteosarcoma cell proliferation potential and promoted osteosarcoma cell apoptosis. 109 Tumor suppressor lncRNAs are involved in regulating human osteosarcoma. The levels of hypoxia-inducible factor-2α (HIF2α) promoter upstream transcript (HIF2PUT), a novel lncRNA, were assessed via quantitative polymerase chain reaction in 17 osteosarcoma tissue specimens, and the data demonstrated that HIF2PUT functions as an osteosarcoma stem cell inhibitor in vitro partly by controlling HIF2α expression. HIF2PUT overexpression markedly inhibited cell proliferation and migration, decreased the percentage of CD133-expressing cells, and impaired the osteosarcoma stem sphere-forming ability of MG63 cells. 110 It has been reported that the HIF2PUT expression levels were positively correlated with HIF2α expression in osteosarcoma tissues. However, HIF2PUT overexpression obviously suppressed cell proliferation and migration, decreased the percentage of CD133-expressing cells, and impaired the osteosarcoma stem sphere-forming ability of MG63 cells. However, HIF2PUT knockdown had the opposite effect. Tumor suppressor candidate 7 (TUSC7) is a potential tumor suppressor that has been shown to inhibit cell proliferation in osteosarcoma. Cong et al. 111 reported that TUSC7 expression was significantly downregulated in osteosarcoma tissues compared with paired non-tumor tissues. Low TUSC7 expression is associated with poor survival (HR = 0.313, 95% confidence interval (CI) 0.092-0.867) in osteosarcoma patients. Loss of TUSC7 copy number is also associated with a poor prognosis (HR = 3.994, 95% CI: 1.147-13.91) in osteosarcoma patients. The author of the above study used two osteosarcoma cell lines, HOS and MG63, to investigate the biological function of TUSC7. Silencing TUSC7 increased osteosarcoma cell proliferation ability and colony formation ability. The cell cycle was not affected by TUSC7 silencing; however, the percentage of apoptotic cells decreased, and the expression levels of several proapoptotic proteins were downregulated. Importantly, xenograft tumor models were established in nude mice using MG63 cells. Silencing TUSC7 significantly promoted tumor growth in vivo in treated mice compared with negativecontrol mice. Thus, TUSC7 may be a tumor suppressor in osteosarcoma. Similarly, Wang et al. 112 determined that TUSC7 is a potential biomarker for NSCLC prognosis and that TUSC7 dysregulation has an important role in NSCLC progression. In their studies, they found that the expression levels of TUSC7 were lower in NSCLC tissues and lung cancer cells compared with that in normal tissues and cells. Lower TUSC7 expression levels in NSCLC tissues were associated with larger tumor sizes and higher TNM stages. Patients with lower TUSC7 expression levels exhibited worse overall survival compared with patients with high TUSC7 expression levels. Univariate and multivariate analyses suggested that low TUSC7 expression was an independent prognostic indicator of a poor prognosis in NSCLC patients. Moreover, TUSC7 upregulation inhibited lung cancer cell proliferation in vitro.
LncRNA and Osteosarcoma Prognosis
Genetic variants of HOTAIR lncRNA contribute to the risk of osteosarcoma. A two-stage, case-control study involving 900 OS patients and 900 controls was performed to evaluate the associations between HOTAIR lncRNA genetic variants and OS risk in the Chinese population, the results of which demonstrated that the C allele of rs7958904 was associated with a significantly decreased OS risk compared with the G allele (OR: 0.77; 95% CI: 0.67-0.90; P = 6.77x10 − 4 ), suggesting that patients with the rs7958904 CC genotype had significantly lower HOTAIR RNA levels compared with patients with other genotypes, as well as a lower OS risk. 113 Ma et al. 114 found that TUG1 was significantly overexpressed in osteosarcoma tissues compared with matched adjacent normal tissues (Po0.01). Moreover, TUG1 levels were strongly correlated with disease status and tumor size, postoperative chemotherapy, and Enneking surgical stage. Furthermore, TUG1 upregulation was strongly correlated with a poor prognosis and was an independent prognostic indicator for overall survival (HR = 2.78; 95% CI: 1.29-6.00; P = 0.009) and progression-free survival (HR = 1.81; 95% CI = 1.01-3.54; P = 0.037). HOTTIP was overexpressed in OS tissues and was correlated with advanced clinical stage and distant metastasis. High HOTTIP expression levels were associated with poor overall survival in OS patients. Moreover, HOTTIP expression was an independent prognostic factor for overall survival in OS patients and may represent a novel prognostic marker and therapeutic target in OS patients. 115 Liu et al.
116
demonstrated that MEG3 lncRNA levels were clearly lower in osteosarcoma tissues compared with that in adjacent nontumor tissues. Patients with low MEG3 lncRNA expression levels exhibited shorter overall survival compared with patients with high expression levels (log-rank test, Po0.05). Furthermore, decreased MEG3 lncRNA expression, advanced clinical stage, and distant metastasis were all independent predictors of shorter overall survival in osteosarcoma patients.
lncRNA and Chemotherapeutic Drug Resistance in Osteosarcoma
Surgery, radiotherapy, and chemotherapy are the three main treatments for cancer. In particular, chemotherapy has an important role in cancer therapy. However, chemotherapeutic drug resistance is the largest obstacle limiting the success of cancer therapy. Large numbers of studies have focused on chemotherapy drug resistance in human osteosarcoma, but the mechanism underlying this resistance remains to be elucidated. In osteosarcoma, chemotherapy drug efficacy is usually limited by acquired resistance to specific drugs, such as doxorubicin and cisplatin. Zhu et al. 117 studied three sets of doxorubicin-resistant MG63/DXR cells and their paired parental MG63 cells and identified 3465 lncRNAs (1761 up and 1704 down) and 3278 mRNAs (1607 up and 1671 down) that were aberrantly expressed in MG63/DXR cells (fold change 42.0, Po0.05 and FDRo0.05). Moreover, an lncRNA-mRNA coexpression network identified lncRNAs, including ENST00000563280 and NR-036444, that interact with genes such as ABCB1, HIF1A, and FOXC2 and may have an important role in doxorubicin resistance in OS. Several lncRNAs have been found to serve as biomarkers predicting the chemoresponses and prognoses of osteosarcoma patients, including ENST00000563280, whose expression level was significantly increased in the tissue specimens of OS patients with poor chemoresponses compared with those with good chemoresponses.
Conclusions and Perspectives
Previous studies have reported that lncRNAs regulate the transcription, stability and translation of protein-coding genes in the mammalian genome, play important roles in regulating protein-coding genes at the transcriptional and posttranscriptional levels, and participate in important biological processes, including cell differentiation, development and human diseases. [118] [119] [120] Human genome studies have shown Long noncoding RNAs Z Yang et al that ∼ 18% of protein-coding genes that produce lncRNAs (10/57) are related to cancer, whereas only 9% of all human protein-coding genes (2147/23621) are related to cancer (chi-square test, P-value: 0.047; hypergeometric probability P-value = 0.018), clearly demonstrating that genes implicated in cancer development have a greater tendency to produce lncRNAs. 121 In this review, we have summarized how lncRNAs regulate cell proliferation, invasion and chemotherapeutic drug resistance in human osteosarcoma patients and osteosarcoma cells. We have also summarized the roles of lncRNAs as prognostic biomarkers in osteosarcoma therapy. Finding promising therapeutic targets for the treatment for human osteosarcoma, especially chemotherapeutic drugresistant osteosarcoma, will be beneficial for patients. However, several questions regarding the involvement of lncRNAs in osteosarcoma remain unexplored and unresolved.
(1) To date, limited studies regarding the involvement of lncRNAs in human osteosarcoma have been published. Although several lncRNAs are known to exert tumorpromoting or tumor-suppressing effects in osteosarcoma species and cancer cell lines, the exact molecular mechanisms underlying these effects remain unclear. Thus, additional investigations are required to elucidate the molecular mechanisms underlying human osteosarcoma progression, metastasis and drug resistance. (2) One lncRNA may be involved in several different signaling pathways associated with cancer development and may have more than one target associated with osteosarcoma proliferation and metastasis. For instance, MALAT1 plays an important role in the PI3K/AKT and RhoA/ROCKs signaling pathways. However, understanding the connections between these signaling pathways, as well as determining whether one of them plays a major role in osteosarcoma development and progression, warrants further study. (3) lncRNAs usually have short half-lives and exhibit low transcript abundance. They need to be transiently expressed in vitro. Additionally, it is necessary to determine how the secondary and tertiary structures of lncRNAs interact with specific protein targets. (4) lncRNAs may represent novel therapeutic targets, which are critical for developing novel strategies for the early diagnosis and treatment of human osteosarcoma. The potential clinical applications of miRNAs warrant investigation.
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